Rein Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Rein Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $3.22 million for the year ending 2025.

  • Rein Therapeutics, Inc. showed a decrease of -75.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
  • XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 12 years of available data (2014 to 2025), Rein Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 48.2%.
  • Historical annual values: Fiscal year 2025: $3.22 million | Fiscal year 2024: $12.87 million | Fiscal year 2023: $17.34 million | Fiscal year 2022: $5.19 million | Fiscal year 2021: $3.60 million | Fiscal year 2020: $7.05 million | Fiscal year 2019: $5.31 million | Fiscal year 2018: $10.64 million | Fiscal year 2017: $11.86 million | Fiscal year 2016: $20.72 million | Fiscal year 2015: $3.77 million | Fiscal year 2014: $6.21 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: